{"id":"https://openalex.org/W2019549804","doi":"https://doi.org/10.1517/14656566.9.5.669","title":"Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care","display_name":"Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care","publication_year":2008,"publication_date":"2008-03-17","ids":{"openalex":"https://openalex.org/W2019549804","doi":"https://doi.org/10.1517/14656566.9.5.669","mag":"2019549804","pmid":"https://pubmed.ncbi.nlm.nih.gov/18345946"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.9.5.669","doi":"https://doi.org/10.1517/14656566.9.5.669","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.9.5.669","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078029213","display_name":"Carolyn Harley","orcid":"https://orcid.org/0000-0002-4003-8316","observed_orcids":["https://orcid.org/0000-0002-4003-8316"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolyn R Harley","raw_affiliation_strings":["i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA. carolyn.harley@i3innovus.com","i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA. carolyn.harley@i3innovus.com","institution_ids":[]},{"raw_affiliation_string":"i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106733906","display_name":"Sanjay K Gandhi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay K Gandhi","raw_affiliation_strings":["AstraZeneca, Wilmington, Delaware, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Wilmington, Delaware, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059547603","display_name":"Herbert C. Heien","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Herbert Heien","raw_affiliation_strings":["i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA +1 650 858 6805; carolyn.harley@i3innovus.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA +1 650 858 6805; carolyn.harley@i3innovus.com","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ken McDonough","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken McDonough","raw_affiliation_strings":["AstraZeneca, Wilmington, Delaware, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Wilmington, Delaware, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071901774","display_name":"Stephanie Nelson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie P Nelson","raw_affiliation_strings":["i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA +1 650 858 6805; carolyn.harley@i3innovus.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i3 Innovus, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA +1 650 858 6805; carolyn.harley@i3innovus.com","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.5897,"has_fulltext":false,"cited_by_count":25,"citation_normalized_percentile":{"value":0.89733438,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"9","issue":"5","first_page":"669","last_page":"676"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":0.949999988079071},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.8700000047683716},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.7559999823570251},{"id":"https://openalex.org/keywords/ldl-c-target-attainment","display_name":"LDL-C goal attainment","score":0.8379999995231628},{"id":"https://openalex.org/keywords/diabetes-mellitus","display_name":"diabetes mellitus","score":0.7699999809265137},{"id":"https://openalex.org/keywords/atorvastatin","display_name":"atorvastatin","score":0.8040000200271606},{"id":"https://openalex.org/keywords/simvastatin","display_name":"simvastatin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pravastatin","display_name":"pravastatin","score":0.9779999852180481},{"id":"https://openalex.org/keywords/fluvastatin","display_name":"fluvastatin","score":0.8659999966621399},{"id":"https://openalex.org/keywords/lovastatin","display_name":"lovastatin","score":0.9940000176429749},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.75},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.7850000262260437},{"id":"https://openalex.org/keywords/managed-care","display_name":"managed care","score":0.7200000286102295},{"id":"https://openalex.org/keywords/usual-care","display_name":"usual care","score":0.6859999895095825},{"id":"https://openalex.org/keywords/statin-comparison","display_name":"statin comparison","score":0.4399999976158142},{"id":"https://openalex.org/keywords/medicare-advantage","display_name":"Medicare Advantage","score":0.3889999985694885},{"id":"https://openalex.org/keywords/cardiovascular-event-prevention","display_name":"cardiovascular event prevention","score":0.39399999380111694},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.3440000116825104}],"concepts":[{"id":"https://openalex.org/C2778417548","wikidata":"https://www.wikidata.org/wiki/Q417942","display_name":"Fluvastatin","level":3,"score":0.9276313781738281},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.92188560962677},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9075750708580017},{"id":"https://openalex.org/C2779519902","wikidata":"https://www.wikidata.org/wiki/Q1240093","display_name":"Pravastatin","level":3,"score":0.8946239352226257},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.7349393963813782},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.6570959091186523},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5885399580001831},{"id":"https://openalex.org/C2776329913","wikidata":"https://www.wikidata.org/wiki/Q670131","display_name":"Simvastatin","level":2,"score":0.5815129280090332},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5732482671737671},{"id":"https://openalex.org/C2778402494","wikidata":"https://www.wikidata.org/wiki/Q599756","display_name":"National Cholesterol Education Program","level":4,"score":0.5447174310684204},{"id":"https://openalex.org/C2776692505","wikidata":"https://www.wikidata.org/wiki/Q412677","display_name":"Pitavastatin","level":3,"score":0.4951743185520172},{"id":"https://openalex.org/C104950815","wikidata":"https://www.wikidata.org/wiki/Q415607","display_name":"HMG-CoA reductase","level":4,"score":0.4817793071269989},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.47979527711868286},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3721470534801483},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.3210395574569702},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.24352014064788818},{"id":"https://openalex.org/C134651460","wikidata":"https://www.wikidata.org/wiki/Q3100717","display_name":"Reductase","level":3,"score":0.09026756882667542},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.0713837742805481},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069059","descriptor_name":"Atorvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077340","descriptor_name":"Fluvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D005229","descriptor_name":"Fatty Acids, Monounsaturated","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008148","descriptor_name":"Lovastatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008329","descriptor_name":"Managed Care Programs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017035","descriptor_name":"Pravastatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017410","descriptor_name":"Practice Guidelines as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019821","descriptor_name":"Simvastatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048909","descriptor_name":"Diabetes Complications","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/14656566.9.5.669","doi":"https://doi.org/10.1517/14656566.9.5.669","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.9.5.669","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:18345946","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18345946","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1502524639","https://openalex.org/W1824295310","https://openalex.org/W1863726591","https://openalex.org/W1947682983","https://openalex.org/W1965012182","https://openalex.org/W1978218523","https://openalex.org/W2001041427","https://openalex.org/W2010173489","https://openalex.org/W2031347540","https://openalex.org/W2031831221","https://openalex.org/W2035081010","https://openalex.org/W2065904318","https://openalex.org/W2074729557","https://openalex.org/W2100270330","https://openalex.org/W2106229961","https://openalex.org/W2106343349","https://openalex.org/W2107295258","https://openalex.org/W2111714105","https://openalex.org/W2115316104","https://openalex.org/W2115728877","https://openalex.org/W2135020991","https://openalex.org/W2144438633","https://openalex.org/W2145866410","https://openalex.org/W2149061221","https://openalex.org/W2154704322","https://openalex.org/W2160810969","https://openalex.org/W2166894879","https://openalex.org/W2169646090","https://openalex.org/W2171596868","https://openalex.org/W2342247435","https://openalex.org/W2477872031","https://openalex.org/W4230870013","https://openalex.org/W4238251256","https://openalex.org/W4238377851","https://openalex.org/W4249825849","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W1965012182","https://openalex.org/W2160810969","https://openalex.org/W1996661696","https://openalex.org/W1997995563","https://openalex.org/W1973523240","https://openalex.org/W3038388482","https://openalex.org/W2013694999","https://openalex.org/W2152065670","https://openalex.org/W2122444136","https://openalex.org/W2905089248"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"compare":[2],"change":[3],"in":[4,23,32,126,217,321],"low-density":[5],"lipoprotein":[6],"cholesterol":[7],"(LDL-C)":[8],"levels":[9,310],"and":[10,49,83,105,130,199,311],"National":[11],"Cholesterol":[12],"Education":[13],"Program":[14],"(NCEP)":[15],"Adult":[16],"Treatment":[17],"Panel":[18],"III":[19,315],"LDL-C":[20,127,134,218,250,309,316],"goal":[21,135,140,251,272,317],"attainment":[22,131],"diabetic":[24,301],"patients":[25,137,150,211,223],"treated":[26,76],"with":[27,77,110,151,155],"rosuvastatin":[28,210,279,303],"versus":[29],"other":[30,256,319],"statins":[31,78,257,320],"a":[33,57,70,213],"large,":[34],"managed":[35],"care":[36],"health":[37,59,119],"plan.":[38,60],"RESEARCH":[39],"DESIGN":[40],"AND":[41],"METHODS:":[42],"This":[43],"retrospective":[44],"cohort":[45],"analysis":[46],"used":[47],"medical":[48],"pharmacy":[50],"claims":[51],"linked":[52],"to":[53,81,248],"laboratory":[54],"results":[55],"from":[56,79,128,219],"commercial/MedicareAdvantage":[58],"Study":[61],"participants":[62],"were":[63,74,84,98,153,244],">or=":[64,106],"18":[65],"years":[66],"of":[67,72,118,132,147,158,167],"age,":[68],"had":[69],"diagnosis":[71],"diabetes,":[73],"newly":[75],"8/1/03":[80],"2/28/05,":[82],"considered":[85],"at":[86,139,307],"high":[87],"risk":[88],"for":[89,101,208,276,282],"cardiovascular":[90],"events":[91],"as":[92],"defined":[93],"by":[94],"NCEP":[95,133,313],"guidelines.":[96],"Subjects":[97],"continuously":[99],"enrolled":[100],"12":[102],"months":[103],"pre-index":[104],"30":[107],"days":[108],"post-index,":[109],"variable":[111],"follow-up":[112],"until":[113],"therapy":[114,160],"discontinuation":[115],"or":[116,236,293],"end":[117],"plan":[120],"eligibility.":[121],"MAIN":[122],"OUTCOME":[123],"MEASURES:":[124],"Change":[125],"baseline,":[129],"among":[136],"not":[138],"before":[141],"starting":[142],"therapy.":[143],"RESULTS:":[144],"A":[145,165],"total":[146,166],"3337":[148],"adult":[149],"diabetes":[152],"identified":[154],"new":[156],"use":[157],"statin":[159],"during":[161],"the":[162,255],"identification":[163],"period.":[164],"9%":[168],"(n":[169,176,182,188,194,201],"=":[170,177,183,189,195,202,228],"301)":[171],"started":[172],"on":[173,179,185,191,197,204],"rosuvastatin,":[174],"49.4%":[175],"1,649)":[178],"atorvastatin,":[180],"20.7%":[181],"690)":[184],"simvastatin,":[186],"7.0%":[187],"234)":[190],"pravastatin,":[192],"11.7%":[193],"391)":[196],"lovastatin":[198,237,291],"2.2%":[200],"72)":[203],"fluvastatin.":[205],"After":[206],"controlling":[207],"covariates,":[209],"experienced":[212],"significantly":[214,245,274],"greater":[215,275],"decrease":[216],"baseline":[220],"(38.7%)":[221],"than":[222,252,281,318],"taking":[224,254,278,284],"atorvastatin":[225,285],"(34.2%)":[226],"(p":[227,239,296],"0.05),":[229],"simvastatin":[230,287],"(31.5%),":[231],"pravastatin":[232,289],"(24.2%),":[233],"fluvastatin":[234,294],"(26.3%)":[235],"(24.9%)":[238],"<":[240,267,297],"0.0001).":[241],"Rosuvastatin":[242],"users":[243],"more":[246,305],"likely":[247],"attain":[249],"those":[253,277,283],"(odds":[258],"ratio:":[259],"0.44,":[260],"0.28,":[261],"0.14,":[262,263],"0.19,":[264],"respectively;":[265],"p":[266],"0.001).":[268,298],"Predicted":[269],"percent":[270],"attaining":[271,312],"was":[273],"(87.3%)":[280],"(76.9%),":[286],"(68.7%),":[288],"(55.0%),":[290],"(55.3%)":[292],"(61.3%)":[295],"CONCLUSION:":[299],"For":[300],"patients,":[302],"is":[304],"effective":[306],"reducing":[308],"ATP":[314],"real-world":[322],"clinical":[323],"practice.":[324]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}